Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

P&G earnings

This article was originally published in The Tan Sheet

Executive Summary

Procter & Gamble estimates first quarter earnings of $.72 per share, an increase of 14% versus the prior-year quarter, company announces during the Prudential Back to School Consumer Conference Sept. 9. The marketer of Crest oral care products also expects organic sales growth in Q1 to be in the 4% to 6% range, excluding the estimated impacts of acquisitions and divestitures as well as foreign exchange. The estimates are based in part on "robust" first-quarter initiatives, the firm notes...

You may also be interested in...



New Filings At The EMA

New medicines under evaluation at the European Medicines Agency.

Formycon And Bioeq Offer Ranibizumab Update

Formycon and partner Bioeq have offered further details on timing for the submission of their FYB201 proposed ranibizumab biosimilar version of Lucentis in Europe, the US and elsewhere.

Oxular Sets Out Eye Disease Plans Armed With $37m

The fresh cash injection will fund Phase II studies evaluating the UK firm's 12-month treatment for diabetic macular edema.

Topics

UsernamePublicRestriction

Register

LL1129949

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel